Age-related Macular Degeneration
📧 Sign up to get email alerts when something new happens for Age-related Macular Degeneration.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-01-05Clinical Trial Update: Prospective triAl of Modified Treat-and-extend Regimens With BroLucizumab in pachychOroid Neovasculopathy [Phase 3]
Phase 3 trial investigating BroLucizumab in pachychoroid neovasculopathy and age-related macular degeneration is currently in an unknown sta…
-
CLINICAL_TRIALS trial_result · 2022-12-22Clinical Trial Update: Alpha MSH in Ocular Disease [NA]
A completed clinical trial investigating Alpha MSH for advanced dry macular degeneration; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-12-06Clinical Trial Update: Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration [Phase 3]
Phase 3 trial evaluating aflibercept after ranibizumab in exudative age-related macular degeneration has completed.
-
CLINICAL_TRIALS trial_result · 2022-11-25Clinical Trial Update: A Phase Ⅱ Clinical Study of Sanhuangjingshimingwan in Wet( Neovascular)Age-related Macular Degeneration(wAMD) Subjects [Phase 2]
Phase 2 clinical study of Sanhuangjingshimingwan in wet age-related macular degeneration completed.
-
CLINICAL_TRIALS trial_result · 2022-10-31Clinical Trial Update: A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration [Phase 2]
Phase 2 trial of multiple-dose intravitreal GEM103 for neovascular age-related macular degeneration was terminated, with results posted in 2…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-09-14Clinical Trial Update: Efficacy and Safety of Intravitreal Conbercept With Modified Treat-and-Extend Regimens in Exudative AMD [Phase 2, Phase 3]
A trial update on intravitreal conbercept using modified treat-and-extend regimens for exudative age-related macular degeneration is being s…
-
CLINICAL_TRIALS trial_result · 2022-09-14Clinical Trial Update: Treatment of Age-related Macular Degeneration Using Retinal Stem and Progenitor Cells [Phase 1, Phase 2]
A clinical trial evaluating retinal stem and progenitor cell therapy for age-related macular degeneration is in Phase 1/Phase 2, with no cur…
-
CLINICAL_TRIALS trial_result · 2022-08-25Clinical Trial Update: Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration [Phase 1, Phase 2]
A clinical trial update on prophylactic ranibizumab for exudative age-related macular degeneration across phase 1 and phase 2 has completed.
-
CLINICAL_TRIALS trial_result · 2022-08-22Clinical Trial Update: Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL) [NA]
Clinical trial update related to Age-related Macular Degeneration in the VITAL study; status and results not clearly specified.
-
CLINICAL_TRIALS trial_result · 2022-08-11Clinical Trial Update: Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD [Phase 2]
Phase 2 trial evaluating the safety and efficacy of ALS-L1023 in combination with ranibizumab for wet age-related macular degeneration has c…
-
FDA approval · 2022-08-02FDA Approved: CIMERLI — Original Application (Coherus BioSciences Inc)
FDA approved CIMERLI (ranibizumab-eqrn) from Coherus as an original Biologics License Application. It is a biosimilar to ranibizumab (Lucent…
-
CLINICAL_TRIALS trial_result · 2022-07-22Clinical Trial Update: Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections [Phase 3]
Phase 3 trial comparing brolucizumab 6 mg every 4 weeks to aflibercept 2 mg every 4 weeks in patients with retinal fluid despite frequent an…
-
FDA label_change · 2022-05-27FDA Approved: BEOVU — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for BEOVU (brolucizumab) submitted by Novartis, resulting in updated labeling.
-
CLINICAL_TRIALS trial_result · 2022-05-12Clinical Trial Update: Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy [Phase 1]
Phase 1 safety and tolerability study of RN6G in subjects with advanced dry age-related macular degeneration including geographic atrophy ha…
-
CLINICAL_TRIALS trial_result · 2022-04-27Clinical Trial Update: Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept [Phase 4]
Phase 4 trial update evaluating plasma VEGF levels before and after intravitreal aflibercept injection in exudative age-related macular dege…
-
CLINICAL_TRIALS trial_result · 2022-04-19Clinical Trial Update: SD-OCT Angiography [NA]
Clinical trial update for SD-OCT Angiography study (NCT02510885) sponsored by Duke University; the trial is terminated, with results posted …
-
CLINICAL_TRIALS trial_result · 2021-09-30Clinical Trial Update: Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration [Phase 3]
Phase 3 trial comparing biosimilar ranibizumab FYB201 to Lucentis in neovascular age-related macular degeneration completed with posted resu…
-
CLINICAL_TRIALS withdrawal · 2021-09-23Clinical Trial Update: Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE) [Phase 3]
Phase 3 trial evaluating brolucizumab 6mg in a treat-and-extend regimen for neovascular age-related macular degeneration with prior anti-VEG…
-
CLINICAL_TRIALS trial_result · 2021-09-17Clinical Trial Update: Cataract and AMD in a Trial of a Multivitamin and Cocoa Extract [Phase 4]
Phase 4 trial update investigating a multivitamin and cocoa extract in cataract and age-related macular degeneration.
-
CLINICAL_TRIALS trial_result · 2021-08-18Clinical Trial Update: An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy [Phase 4]
Phase 4 open-label study assessing aflibercept monotherapy for polypoidal choroidal vasculopathy, completed with posted results in 2021.
-
CLINICAL_TRIALS trial_result · 2021-07-13Clinical Trial Update: Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects [Phase 2]
Phase 2 trial evaluating intravitreal DE-122 plus Lucentis versus Lucentis alone for wet age-related macular degeneration completed with pos…
-
FDA approval · 2021-07-09FDA Approved: VISUDYNE — Supplemental Application (Bausch & Lomb Incorporated)
The FDA approved a supplemental application for VISUDYNE (verteporfin for injection) from Bausch & Lomb Incorporated, updating the product a…
-
CLINICAL_TRIALS trial_result · 2021-05-21Clinical Trial Update: A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD) [Phase 3]
Phase 3 trial comparing SB11 (ranibizumab biosimilar) to Lucentis in neovascular age-related macular degeneration has completed with results…
-
CLINICAL_TRIALS trial_result · 2021-05-21Clinical Trial Update: Global Atrophie Biomarker Evaluation Study (GABiE)
Global Atrophie Biomarker Evaluation Study (GABiE) terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-05-19Clinical Trial Update: Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration [NA]
A completed clinical trial investigating non-damaging photothermal therapy for non-exudative age-related macular degeneration with results p…